Investment
Features
FeesSafety
Academy
More
Pluang+

Compare McKesson Corporation (MCK) vs Rocket Lab USA Inc (RKLB) Price & Performance

McKesson CorporationTrade
Rocket Lab USA IncTrade

Price performance (Past 24H)

Key statistics

McKesson Corporation vs Rocket Lab USA Inc — how do they compare? McKesson Corporation trades at $824 (market cap $97.35B), while Rocket Lab USA Inc trades at $68.67 (market cap $41.08B). The key difference: McKesson Corporation is far larger — about 2.4× Rocket Lab USA Inc's market cap, and McKesson Corporation pays a 0.39% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals.

MCKRKLB
Market Cap
$97.35B$41.08B
Sector
HealthTechnology
52-Week High
$995.69$150.23
52-Week Low
$659.01$39.48
Enterprise Value
$101.98B$39.83B
Dividend Yield
0.39%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

McKesson Corporation

McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.

The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.

Rocket Lab USA Inc

Rocket Lab (RKLB) trades at $65.74, down 2.78% on the day, reflecting a bearish technical trend with support at $63. The company shows strong revenue growth with $601.80M in 2025 but remains unprofitable with a net loss of $198.21M. Recent news highlights competition with SpaceX and a potential catalyst from the Neutron rocket's development. Analyst consensus is overwhelmingly bullish with a $116.90 price target, though technical indicators signal near-term caution.

The outlook for RKLB hinges on execution of its growth strategy and path to profitability. Investment opportunity lies in its expanding launch contracts and competitive positioning in the space sector. Key risks include persistent cash burn, intense competition, and reliance on successful Neutron launches. Investors should weigh strong analyst optimism against fundamental challenges and technical weakness.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK

About Rocket Lab USA Inc

Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.

Read more on RKLB